Evidence map›Paper›PMID 40450581›Full record

ArticleHuman molecular genetics2025

Diverse effects of coexpression of human SOD1 variants on motor neuron disease.

Eiichi Tokuda, Laura Leykam, Per Zetterström, Thomas Brännström, Peter M Andersen, Stefan L Marklund

Abstract read
In one paragraph

Article in Human molecular genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eiichi TokudaDepartment of Medical Biosciences, Umeå University, Umeå, SE 901 85, Sweden.ORCID 0000-0002-7690-3025
Laura LeykamDepartment of Medical Biosciences, Umeå University, Umeå, SE 901 85, Sweden.ORCID 0009-0005-9020-3817
Per ZetterströmDepartment of Medical Biosciences, Umeå University, Umeå, SE 901 85, Sweden.ORCID 0000-0001-8718-3249
Thomas BrännströmDepartment of Medical Biosciences, Umeå University, Umeå, SE 901 85, Sweden.ORCID 0000-0002-4201-8204
Peter M AndersenDepartment of Clinical Science, Neurosciences, Umeå University, Umeå, SE 901 85, Sweden.ORCID 0000-0003-0094-5429
Stefan L MarklundDepartment of Medical Biosciences, Umeå University, Umeå, SE 901 85, Sweden.ORCID 0000-0002-3270-2854

Funding

Knut and Alice Wallenberg Foundation 2012.0091Knut and Alice Wallenberg Foundation 2014.0305Knut and Alice Wallenberg Foundation 2020.0232Swedish Brain Foundation 2012-0262Swedish Brain Foundation 2012-0305Swedish Brain Foundation 2013-0279Swedish Brain Foundation 2016-0303Swedish Brain Foundation 2018-0310Swedish Brain Foundation 2020-0353Swedish Brain Foundation 2022-0309Swedish Research Council 2012-3167Swedish Research Council 2017-03100Torsten and Ragnar Söderberg Foundation, Umeå University Insamlingsstiftelsen 2.1.12-1605-14Torsten and Ragnar Söderberg Foundation, Umeå University Insamlingsstiftelsen 223-1881-13Torsten and Ragnar Söderberg Foundation, Umeå University Insamlingsstiftelsen 223-2808-12Västerbotten County Council 56103-7002829
6 · The paper itself

Abstract

Mutations in superoxide dismutase-1 (SOD1) are a common cause of amyotrophic lateral sclerosis (ALS). Inheritance is as a rule dominant, but in carriers of the most common mutation, D90A, disease can develop in both homozygous and, more rarely, in heterozygous individuals with unexplained differences in clinical presentation. There is mounting evidence that prion-like spread of SOD1 aggregation is the primary cause of the disease. Two different strains of aggregates have been found to arise in human SOD1 (hSOD1) transgenic mouse models of ALS. Strain A is formed by most mutants including hSOD1G85R and hSOD1WT, whereas hSOD1D90A transgenic mice form a distinct strain B in addition to A. To explore the effects of aggregate strain propensities when hSOD1 variants are coexpressed, we generated digenic hSOD1G85R/WT and hSOD1G85R/D90A mice. Coexpression of hSOD1WT considerably shortened the lifespan of hSOD1G85R mice to the extent expected from the neurotoxicities of the variants alone. In contrast, coexpression of hSOD1D90A had a minimal effect on survival, far smaller than expected. Moreover, time from onset to the end stage was markedly prolonged in the hSOD1G85R/D90A mice. Aggregation of hSOD1 developed concomitantly with motor neuron disease, and the aggregates contained large amounts of both coexpressed variants in both digenic models. Our findings suggest that hSOD1WT has high a capacity to coaggregate with mutants and enhance neurotoxicity. Such interactions may be restricted by differences in strain propensities, which may contribute to the primarily recessive inheritance associated with the hSOD1D90A mutation.

Indexed as

Amyotrophic Lateral SclerosisMotor Neuron DiseaseSuperoxide DismutaseSuperoxide Dismutase-1AnimalsDisease Models, AnimalHumansMiceMice, TransgenicMotor NeuronsMutationSOD1 protein, humanSuperoxide DismutaseSuperoxide Dismutase-1Aggregate strainsBladder control impairmentCoexpressionStrain selectionSuperoxide dismutase-1

Identifiers

PMID40450581
PMCPMC12361113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.